Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the pharmacokinetics and pharmacodynamics of
IPX054, carbidopa-levodopa immediate-release tablets, and carbidopa-levodopa
controlled-release tablets in subjects with idiopathic Parkinson's disease.
Phase:
Phase 2
Details
Lead Sponsor:
IMPAX Laboratories, Inc. Impax Laboratories, LLC
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa